世界の百日咳治療市場の規模、シェア、傾向分析レポート – 業界の概要と2032年までの予測

百日咳治療市場分析

百日咳治療市場は、世界的に百日咳の罹患率が上昇していることに牽引されており、この病気と闘うためのワクチン、抗生物質、その他の治療法の需要が高まっています。百日咳は伝染性の高い呼吸器疾患で、主に乳幼児に発症しますが、あらゆる年齢層の人に発症​​する可能性があります。市場は、ワクチン開発の進歩、政府の予防接種プログラム、早期診断と治療に対する意識の高まりなどの要因の影響を受けます。最近の動向としては、症状の重症度を軽減し合併症を防ぐことを目的としたワクチン製剤の改善や新しい抗生物質治療の導入が挙げられます。製薬会社はイノベーションに注力し、製品ポートフォリオを拡大するとともに、混合ワクチンの研究の増加も市場の成長を形作っています。公衆衛生イニシアチブへの注目の高まりと新しい治療オプションの出現が相まって、今後数年間の市場拡大を支えると予想されます。

百日咳治療市場規模

世界の百日咳治療市場規模は2024年に38億米ドルと評価され、2032年までに62億4,000万米ドルに達すると予測されており、2025年から2032年の予測期間中のCAGRは6.40%です。市場価値、成長率、セグメンテーション、地理的範囲、主要プレーヤーなどの市場シナリオに関する洞察に加えて、Data Bridge Market Researchがまとめた市場レポートには、詳細な専門家分析、患者の疫学、パイプライン分析、価格分析、規制枠組みも含まれています。

百日咳治療市場の動向

「混合ワクチンの開発」

百日咳の発症率の上昇と効果的な予防および治療への重点の高まりにより、百日咳治療市場は著しい成長を遂げています。市場はワクチン製剤および抗生物質療法の進歩とともに進化しています。重要な傾向の 1 つは、百日咳を含む複数の疾患を予防する混合ワクチンの開発であり、これによりワクチン接種の普及が促進され、治療費が削減されています。さらに、抗生物質治療の革新は、症状の重症度を軽減し、合併症を予防し、早期介入を支援することを目的としています。百日咳予防に関する意識の向上と診断ツールの改善に重点が置かれていることで、市場の需要がさらに高まっています。全体として、政府および医療提供者が効果的な百日咳管理戦略を優先するにつれて、市場は拡大しています。

レポートの範囲と百日咳治療市場のセグメンテーション

Pertussis Treatment Market Definition

Pertussis, also known as whooping cough, is a highly contagious respiratory disease caused by the bacterium bordetella pertussis. It is characterized by severe coughing fits that can make breathing difficult, often followed by a "whooping" sound as the person inhales deeply. The disease primarily affects infants and young children and impact adolescents and adults. Pertussis spreads through respiratory droplets when an infected person coughs or sneezes. Early symptoms resemble those of a common cold, such as a runny nose, sneezing, and mild cough, but these progress to severe coughing paroxysms.

Pertussis Treatment Market Dynamics

Drivers

• Rising Incidence of Pertussis

The increasing incidence of whooping cough, particularly among infants and young children, is a significant driver for the pertussis treatment market. Infants, who are most vulnerable to severe complications from pertussis, often require immediate medical intervention. The rising number of reported cases globally has heightened the need for effective treatment options, including antibiotics and supportive care. This surge in cases is prompting healthcare providers and governments to focus on improving diagnosis, prevention, and treatment strategies. As the disease continues to affect young populations, there is growing demand for both therapeutic solutions and vaccination efforts, further propelling market growth.

• Improved Antibiotic Therapies

The development of more effective antibiotics and treatments for pertussis is a key driver of growth in the pertussis treatment market. New antibiotics, such as azithromycin and clarithromycin, have shown greater efficacy in reducing the severity and duration of the disease, particularly when administered early. These advancements help prevent complications, minimize the risk of transmission, and enhance recovery rates, especially in vulnerable populations such as infants. As the medical community continues to develop and introduce improved therapeutic options, the demand for these treatments is increasing. This supports better patient outcomes contributes to the overall expansion of the pertussis treatment market.

Opportunities

• Advancements in Vaccination Programs

Efforts to expand vaccination programs globally, especially in emerging markets, present a significant opportunity for growth in the pertussis treatment market. As more countries invest in immunization campaigns to combat pertussis, the demand for both preventive and therapeutic options rises. These initiatives increase vaccination coverage and heighten awareness of the disease, leading to earlier diagnosis and treatment. In emerging markets where healthcare infrastructure is improving, there is a growing need for effective treatment options, including antibiotics and supportive care, alongside vaccination. This dual approach of prevention and treatment is expected to drive overall market demand and expansion.

• Rise in Advanced Diagnostic Tools

The rise in early detection methods for pertussis presents a significant opportunity for market players to innovate and develop advanced diagnostic tools. As healthcare systems increasingly focus on timely diagnosis to prevent the spread of pertussis, the demand for rapid, accurate diagnostic solutions is growing. These innovations, such as PCR-based tests and molecular diagnostic kits, enable early identification of the disease, leading to prompt treatment and better patient outcomes. By integrating these diagnostic tools with existing treatment solutions, companies can offer comprehensive care packages, improving overall disease management. This integration represents a promising market opportunity, particularly in regions with rising pertussis cases.

Restraints/Challenges

• Global Health Disparities

Disparities in healthcare access, especially in developing countries, present a significant challenge for the pertussis treatment market. In many low-income regions, limited healthcare infrastructure, lack of trained medical professionals, and insufficient funding for immunization programs hinder the widespread distribution of pertussis vaccines and effective treatment options. These disparities result in delayed diagnosis and treatment, contributing to higher morbidity and mortality rates. Additionally, the high cost of healthcare and medications in these areas prevents many from accessing necessary treatments. As a result, these challenges restrict the overall market potential for pertussis treatment, particularly in emerging markets with underserved populations.

•  High Cost of Treatment

In some regions, the high cost of pertussis treatment, including vaccines and antibiotics, serves as a significant market restraint. In low-income and emerging markets, where healthcare budgets are limited, the cost of both preventive and therapeutic options can be prohibitive for a large portion of the population. This financial barrier results in low vaccination rates and delayed or inadequate treatment, hindering efforts to control the spread of pertussis. As a result, market adoption is slowed in these regions, limiting the potential for widespread use of pertussis treatments and delaying overall market growth in developing economies.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Pertussis Treatment Market Scope

The market is segmented on the basis of product, type, diagnosis, treatment, medication, route of administration, application, end users, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Whole-Cell Vaccines
• Acellular Vaccines
• Others

Type

• Azithromycin
• Clarithromycin
• Erythromycin
• Other

Diagnosis

• Chest X-Ray
• Blood Tests
• Others

Treatment

• Medication
• Vaccination
• Others

Medication

• Antibiotics
• Cough Suppressants
• Others

Route of Administration

• Oral
• Injectable
• Others

Application

• Children
• Adults

End Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• Others

Pertussis Treatment Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, product, type, diagnosis, treatment, medication, route of administration, application, end users, and distribution channel referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America leads the pertussis treatment market, driven by a rising demand for treatments targeting newborns and infants. The region's high healthcare expenditure enables access to advanced treatment options, further supporting market growth. Additionally, strong government initiatives focused on providing reliable healthcare solutions play a crucial role in boosting the demand for pertussis treatments.

Europe is expected to experience notable growth in the pertussis treatment market, driven by its substantial share of the global economy. The region’s rapidly improving healthcare infrastructure is enhancing access to advanced treatments and vaccination programs. Additionally, strong economic development in many European countries supports increased investment in public health initiatives, further contributing to market growth.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Pertussis Treatment Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Pertussis Treatment Market Leaders Operating in the Market Are:

• Sanofi (France)
• Takeda Pharmaceutical Company Limited (Japan)
• Biological E Limited (India)
• Astellas Pharma Inc. (Japan)
• Johnson & Johnson Services, Inc. (U.S.)
• Novartis AG (Switzerland)
• Merck & Co., Inc. (U.S.)
• GSK plc. (U.K.)
• Mitsubishi Tanabe Pharma Corporation (Japan)
• Pfizer Inc. (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Panacea Biotec (India)
• Serum Institute of India Pvt. Ltd. (India)
• Bharat Biotech (India)
• ILiAD Biotechnologies (U.S.)
• Eisai Co., Ltd. (Japan)

Latest Developments in Pertussis Treatment Market

• In February 2022, GlaxoSmithKline initiated a Phase III clinical trial to evaluate the safety and immune response of an unadjuvanted RSV maternal vaccine. The study focuses on healthy non-pregnant women aged 9 to 49 years. This investigation aims to assess the potential of the vaccine in preparing maternal immunity for the prevention of respiratory syncytial virus (RSV)
• 2021年2月、グラクソ・スミスクラインは、MCM BVのVaxelisワクチンの安全性と免疫原性を自社のInfanrix Hexaワクチンと比較する第IV相臨床試験を開始しました。この研究は、生後6～12週の健康な乳児と幼児を対象としています。目標は、幼児に投与した場合の両ワクチンの有効性と安全性プロファイルを評価することです。
• サノフィは2021年1月、南アフリカ共和国で第IV相臨床試験を開始し、破傷風、ジフテリア、百日咳、ポリオを予防するTdap-IPVワクチンによるブースター接種に対する免疫反応を評価した。この試験は、個人の免疫力を高めるワクチンの有効性を評価することを目的としている。この調査は、ワクチン接種戦略と公衆衛生の成果を改善するためのサノフィの継続的な取り組みの一環である。

SKU-50276